Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction: A Double-blind Randomized Controlled Phase IV Trial (VASCEND)
Phase of Trial: Phase IV
Latest Information Update: 12 Dec 2018
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Valsartan
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms VASCEND
- 03 Dec 2018 Planned End Date changed from 24 Dec 2018 to 30 Jun 2019.
- 03 Dec 2018 Planned primary completion date changed from 1 Oct 2018 to 30 Jun 2019.
- 02 Jun 2017 New trial record